BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/13/2015 3:33:00 PM | Browse: 503 | Download: 632
Publication Name World Journal of Ophthalmology
Manuscript ID 17182
Country/Territory United States
2015-02-22 09:39
Peer-Review Started
2015-02-22 16:53
To Make the First Decision
2015-06-03 14:39
Return for Revision
2015-06-04 16:21
2015-06-23 00:00
Second Decision
2015-08-07 17:47
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-08-14 16:19
Articles in Press
2015-08-14 16:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-10-30 20:38
Publish the Manuscript Online
2015-11-13 15:33
ISSN 2218-6239 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Ophthalmology
Manuscript Type Editorial
Article Title Curing diabetic retinopathy: Is a strategy emerging?
Manuscript Source Invited Manuscript
All Author List Michael W Stewart
Funding Agency and Grant Number
Corresponding author Michael W Stewart, MD, Department of Ophthalmology, Mayo Clinic Florida, 4500 San Pablo Rd., Jacksonville, FL 32224, United States. stewart.michael@mayo.edu
Keywords Diabetic macular edema; Ranibizumab; Aflibercept; Diabetic retinopathy; Vascular endothelial growth factor
Core Tip Drugs that prevent the binding of vascular endothelial growth factor (VEGF) produce greater gains in best corrected visual than can be achieved with laser photocoagulation. The recently completed pivotal phase Ⅲ trials showed that regular injections of ranibizumab and aflibercept over 2 years also improved the severity of diabetic retinopathy (DR). Both drugs have now been approved for the treatment of DR in patients with diabetic macular edema (DME) thereby allowing physicians to consider VEGF inhibition to improve DR in patients with vision threatening DME.
Publish Date 2015-11-13 15:33
Citation Stewart MW. Curing diabetic retinopathy: Is a strategy emerging? World J Ophthalmol 2015; 5(4): 142-144
Url http://www.wjgnet.com/2218-6239/full/v5/i4/142.htm
DOI http://dx.doi.org/10.5318/wjo.v5.i4.142
Full Article (PDF) WJO-5-142.pdf
Full Article (Word) WJO-5-142.doc
Manuscript File 17182-Review.docx
Answering Reviewers 17182-Answering reviewers.pdf
Audio Core Tip 17182-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 17182-Conflict-of-interest statement.pdf
Copyright License Agreement 17182-Copyright assignment.pdf
Peer-review Report 17182-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 17182-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 17182-Scientific misconduct check.pdf
Scientific Editor Work List 17182-Scientific editor work list.pdf